The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

Novo Nordisk markets its blockbuster semaglutide (GLP-1) medicines as Ozempic pre-filled pens and Rybelsus oral ... Several companies like Amgen AMGN and Viking Therapeutics VKTX are making ...

14 days Prescribing information Etanercept powder Enbrel (Immunex Corporation [Amgen and Wyeth Pharmaceuticals]) 7 days Manufacturer Etanercept prefilled syringe Enbrel (Immunex Corporation [Amgen ...

The EU approval for the pen injector has come ahead of the US, where Tezspire has been sold by AZ's partner Amgen since the start of 2022. Uptake in the US has exceeded expectations, with Amgen ...

Novo Nordisk markets its blockbuster semaglutide (GLP-1) medicines as Ozempic pre-filled pens and Rybelsus oral ... In November 2024, Amgen announced 52-week top-line data from a phase II study ...

This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita ... two pre-filled pens or syringes.

In July 2024, Darzalex was approved for frontline treatment, joining proteasome inhibitors from Takeda and Amgen. Sanofi’s Sarclisa is also ... “I want a red pen, and I want to go find every medical ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this ...